



Drug Candidates for Allergic Diseases

Guest Editor:

Prof. Dr. Luis Manuel Teran

Department of Immunogenetics
and Allergy, Instituto Nacional
Enfermedades Respiratorias
Ismael Cosío Villegas, México
City, Mexico

Deadline for manuscript
submissions:

closed (25 April 2025)

Message from the Guest Editor

Over the last two decades, novel drugs have emerged paving the way for personalized management of allergic diseases. Bronchoscopy studies and mouse models of asthma provided the initial insights into the mechanisms of allergic inflammation establishing the role of Th2 type 2 cytokines including IL-4, IL-5 IL-13 that led to the development of several monoclonal antibodies (mAbs) targeting these cytokines. Omalizumab was the first mAb used successfully to treat severe asthma patients. Then, other drugs emerged including antibodies that block IL-5 (mepolizumab, reslizumab) and the IL-5 receptor (benralizumab), the IL-4/IL-13 receptor alpha chain (dupilumab) and the thymic stromal lymphopoietin (Tezepelumab). These novel biologicals have been shown to be a good alternative therapies to corticosteroids particularly in severe asthma management that improved the quality of life of many patients. Currently, a number of novel antagonists targeting other inflammatory mediators are still in pre-clinical stages.

This special edition assembles a series of articles that examine the effects of novel drugs in allergic disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)